Surgi-One will distribute the product, which is cleared for use in spine and general orthopedic procedures, the orthobiologics company said in a Nov. 5 news release.
I-Factor+ Matrix uses a peptide technology to promote bone growth through cell attraction, attachment and activation.
The FDA is evaluating the product in an investigational device exemption study for lumbar fusions.
I-Factor+ Matrix has not been approved for use in the U.S.
More articles on biologics:
Orthopedic surgery has 3rd highest gender wage gap among medical specialties, report finds
A timeline of Medtronic’s 7 deals so far in 2020
Robots will never replace surgeons, but can prove useful partners: 3 spine surgeons weigh in
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
